Insulin glargine's main metabolic effect as metabolite M1

October 25, 2012
Insulin glargine's main metabolic effect as metabolite M1
For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration is in the form of its metabolite M1, according to a study published online Oct. 18 in Diabetes Care.

(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration is in the form of its metabolite M1, according to a study published online Oct. 18 in Diabetes Care.

To examine the concentration of plasma and its metabolites after subcutaneous dosing, Paola Lucidi, M.D., Ph.D., from the University of Perugia in Italy, and colleagues performed a 32-hour euglycemic glucose clamp study (0.4 units/kg glargine after one week of daily glargine administration) in nine patients with . A -tandem mass spectrometry assay was used to measure glargine, M1, and M2.

The researchers found that, in five out of nine patients, glargine was detected at negligible concentrations and at few time points. M1 exhibited the same pattern as traditional radioimmunoassay-measured plasma insulin and was detected in all patients. There was no detection of M2 at all.

"In conclusion, after subcutaneous injection of a therapeutic dose in glargine-treated type 2 diabetic subjects, glargine is only transiently, and at minimal concentration, detectable in plasma, whereas its metabolite M1 accounts for most (>90 percent) of the plasma insulin concentration," the authors write. "Thus, in vivo, glargine does not exert its long-acting directly as glargine but predominantly via its main metabolite M1."

Several authors disclosed financial ties to pharmaceutical companies, including sanofi-aventis, which funded the study.

Explore further: Experimental insulin drug prevents low blood sugar

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Experimental insulin drug prevents low blood sugar

June 25, 2012
An experimental insulin drug prevented low blood sugar among diabetic patients more often than a popular drug on the market, a new study finds. The results will be presented at The Endocrine Society's 94th Annual Meeting ...

The effect of insulin glargine and fish oil supplements on atherosclerosis progression

August 27, 2012
A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared ...

Recommended for you

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.